| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 07/12/2023 | 16.46% | Benchmark | $47 → $53 | Maintains | Buy |
| 05/08/2023 | 9.87% | JP Morgan | $45 → $50 | Maintains | Overweight |
| 03/07/2023 | 3.27% | Keybanc | $45 → $47 | Maintains | Overweight |
| 02/06/2023 | -1.12% | Cowen & Co. | $37 → $45 | Maintains | Outperform |
| 02/03/2023 | 3.27% | Benchmark | $37 → $47 | Maintains | Buy |
| 02/03/2023 | -1.12% | Keybanc | $36 → $45 | Maintains | Overweight |
| 12/05/2022 | -20.9% | Keybanc | $33 → $36 | Maintains | Overweight |
| 08/05/2022 | -27.49% | Keybanc | $31 → $33 | Maintains | Overweight |
| 08/05/2022 | -27.49% | Wolfe Research | → $33 | Upgrades | Peer Perform → Outperform |
| 07/08/2022 | -31.88% | Keybanc | $34 → $31 | Maintains | Overweight |
| 05/05/2022 | -25.29% | Keybanc | $31 → $34 | Maintains | Overweight |
| 04/04/2022 | -31.88% | Keybanc | $28 → $31 | Maintains | Overweight |
| 02/18/2022 | -34.08% | Benchmark | $26 → $30 | Maintains | Buy |
| 02/18/2022 | -38.48% | Keybanc | $26 → $28 | Maintains | Overweight |
| 02/07/2022 | -36.28% | Barclays | $23 → $29 | Maintains | Overweight |
| 02/04/2022 | -42.87% | Keybanc | $21 → $26 | Maintains | Overweight |
| 01/11/2022 | -49.46% | Cowen & Co. | $22 → $23 | Upgrades | Market Perform → Outperform |
| 01/07/2022 | — | Berenberg | Upgrades | Hold → Buy | |
| 12/21/2021 | -53.86% | Keybanc | $23 → $21 | Maintains | Overweight |
| 11/17/2021 | -60.45% | Wolfe Research | → $18 | Initiates Coverage On | → Peer Perform |
| 10/15/2021 | -49.46% | JP Morgan | → $23 | Upgrades | Neutral → Overweight |
| 09/28/2021 | -49.46% | Keybanc | $27 → $23 | Maintains | Overweight |
| 07/07/2021 | -51.66% | B of A Securities | $15 → $22 | Upgrades | Underperform → Neutral |
| 05/04/2021 | -40.67% | Keybanc | $25 → $27 | Maintains | Overweight |
| 03/16/2021 | -42.87% | Barclays | $16 → $26 | Upgrades | Equal-Weight → Overweight |
| 01/15/2021 | -45.07% | Seaport Global | → $25 | Initiates Coverage On | → Buy |
| 12/07/2020 | -45.07% | Keybanc | $15 → $25 | Maintains | Overweight |
| 12/04/2020 | — | Barclays | Upgrades | Underweight → Equal-Weight | |
| 12/04/2020 | -53.86% | Benchmark | → $21 | Upgrades | Hold → Buy |
| 08/13/2020 | — | Cowen & Co. | Downgrades | Outperform → Market Perform | |
| 06/08/2020 | — | B of A Securities | Downgrades | Buy → Underperform | |
| 04/17/2020 | -64.84% | JP Morgan | $21 → $16 | Maintains | Neutral |
| 04/15/2020 | -67.04% | Keybanc | $18 → $15 | Maintains | Overweight |
| 03/20/2020 | — | Barclays | Downgrades | Equal-Weight → Underweight | |
| 03/12/2020 | -60.45% | Keybanc | $26 → $18 | Maintains | Overweight |
| 02/05/2020 | -47.26% | CFRA | $25 → $24 | Maintains | Buy |
| 02/05/2020 | -42.87% | Keybanc | $25 → $26 | Maintains | Overweight |
| 01/16/2020 | — | Benchmark | Initiates Coverage On | → Hold | |
| 01/16/2020 | -45.07% | Keybanc | $28 → $25 | Maintains | Overweight |
| 01/10/2020 | — | Berenberg | Downgrades | Buy → Hold | |
| 01/08/2020 | -51.66% | Barclays | $31 → $22 | Downgrades | Overweight → Equal-Weight |
| 10/15/2019 | — | Longbow Research | Downgrades | Neutral → Underperform | |
| 10/14/2019 | -38.48% | Keybanc | $33 → $28 | Maintains | Overweight |
| 10/10/2019 | -45.07% | Goldman Sachs | → $25 | Upgrades | Neutral → Buy |
| 09/25/2019 | -53.86% | Buckingham Research | $27 → $21 | Maintains | Neutral |
| 07/18/2019 | — | Longbow Research | Downgrades | Buy → Neutral | |
| 05/06/2019 | — | Buckingham Research | Downgrades | Buy → Neutral | |
| 05/06/2019 | -40.67% | Buckingham Research | $40 → $27 | Downgrades | Buy → Neutral |
| 04/24/2019 | -25.29% | Keybanc | $33 → $34 | Maintains | Overweight |
| 04/18/2019 | -12.11% | Buckingham Research | $45 → $40 | Maintains | Buy |
| 04/12/2019 | -38.48% | Macquarie | $34 → $28 | Downgrades | Outperform → Neutral |
| 02/14/2019 | — | Macquarie | Initiates Coverage On | → Outperform | |
| 12/06/2018 | -23.09% | Berenberg | → $35 | Initiates Coverage On | → Buy |
| 11/06/2018 | -25.29% | Longbow Research | → $34 | Upgrades | Neutral → Buy |
| 10/24/2018 | -38.48% | JP Morgan | → $28 | Upgrades | Underweight → Neutral |
| 08/08/2018 | -5.52% | Buckingham Research | $40 → $43 | Maintains | Buy |
| 07/30/2018 | -14.3% | Barclays | $36 → $39 | Maintains | Overweight |
| 07/26/2018 | -29.69% | Keybanc | $31 → $32 | Maintains | Overweight |
| 07/25/2018 | -25.29% | B of A Securities | $32 → $34 | Maintains | Buy |
What is the target price for ATI (ATI)?
The latest price target for ATI (NYSE: ATI) was reported by Benchmark on July 12, 2023. The analyst firm set a price target for $53.00 expecting ATI to rise to within 12 months (a possible 16.46% upside). 9 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for ATI (ATI)?
The latest analyst rating for ATI (NYSE: ATI) was provided by Benchmark, and ATI maintained their buy rating.
When is the next analyst rating going to be posted or updated for ATI (ATI)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of ATI, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for ATI was filed on July 12, 2023 so you should expect the next rating to be made available sometime around July 12, 2024.
Is the Analyst Rating ATI (ATI) correct?
While ratings are subjective and will change, the latest ATI (ATI) rating was a maintained with a price target of $47.00 to $53.00. The current price ATI (ATI) is trading at is $45.51, which is out of the analyst's predicted range.